journal article·2023-02-09Open access

Effervescent cannabidiol solid dispersion-doped dissolving microneedles for boosted melanoma therapy via the “TRPV1-NFATc1-ATF3” pathway and tumor microenvironment engineering

Jiachen Shi, Qiuling Ma, Wenting Su, Congyan Liu, Huangqin Zhang, Yuping Liu, Xiaoqi Li, Xi Jiang, Chang Ge, Fei Kong, Yan Chen, Ding Qu

Biomaterials Research· Volume 27· Issue 1

Abstract

Abstract Background Conventional dissolving microneedles (DMNs) face significant challenges in anti-melanoma therapy due to the lack of active thrust to achieve efficient transdermal drug delivery and intra-tumoral penetration. Methods In this study, the effervescent cannabidiol solid dispersion-doped dissolving microneedles (Ef/CBD-SD@DMNs) composed of the combined effervescent components (CaCO 3 & NaHCO 3 ) and CBD-based solid dispersion (CBD-SD) were facilely fabricated by the “one-step micro-molding” method for boosted transdermal and tumoral delivery of cannabidiol (CBD). Results Upon pressing into the skin, Ef/CBD-SD@DMNs rapidly produce CO 2 bubbles through proton elimination, significantly enhancing the skin permeation and tumoral penetration of CBD. Once reaching the tumors, Ef/CBD-SD@DMNs can activate transient receptor potential vanilloid 1 (TRPV1) to increase Ca 2+ influx and inhibit the downstream NFATc1-ATF3 signal to induce cell apoptosis. Additionally, Ef/CBD-SD@DMNs raise intra-tumoral pH environment to trigger the engineering of the tumor microenvironment (TME), including the M1 polarization of tumor-associated macrophages (TAMs) and increase of T cells infiltration. The introduction of Ca 2+ can not only amplify the effervescent effect but also provide sufficient Ca 2+ with CBD to potentiate the anti-melanoma efficacy. Such a “one stone, two birds” strategy combines the advantages of effervescent effects on transdermal delivery and TME regulation, creating favorable therapeutic conditions for CBD to obtain stronger inhibition of melanoma growth in vitro and in vivo. Conclusions This study holds promising potential in the transdermal delivery of CBD for melanoma therapy and offers a facile tool for transdermal therapies of skin tumors.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Advancements in Transdermal Drug Delivery · Cannabis and Cannabinoid Research · Toxin Mechanisms and Immunotoxins

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, China.

Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, China.

Funding

National Natural Science Foundation of China · Natural Science Foundation of Jiangsu Province · General Project of Jiangsu Provincial Health Commission · the Open Project of Chinese Materia Medica First-Class Discipline of Nanjing University of Chinese Medicine · Six Talent Peaks Project in Jiangsu Province · “333 Project” of Jiangsu Province

References (44)

Show source-provided references
1. 10.1001/jamadermatol.2022.016010.1001/jamadermatol.2022.0160 ↗
2. 10.1016/j.jaad.2021.09.07510.1016/j.jaad.2021.09.075 ↗
3. 10.1016/j.jid.2018.03.151010.1016/j.jid.2018.03.1510 ↗
4. 10.1021/acs.jnatprod.5b0112710.1021/acs.jnatprod.5b01127 ↗
5. 10.1155/2019/736287510.1155/2019/7362875 ↗
6. 10.5582/bst.8.110.5582/bst.8.1 ↗
7. 10.1016/j.apsb.2021.11.00110.1016/j.apsb.2021.11.001 ↗
8. 10.1016/j.jconrel.2021.05.00510.1016/j.jconrel.2021.05.005 ↗
9. 10.1016/j.jconrel.2022.09.02510.1016/j.jconrel.2022.09.025 ↗
10. 10.1002/anie.20221479510.1002/anie.202214795 ↗
11. 10.1016/j.biopha.2021.11239310.1016/j.biopha.2021.112393 ↗
12. 10.1021/acsnano.2c0809810.1021/acsnano.2c08098 ↗
13. 10.1002/adma.20220996610.1002/adma.202209966 ↗
14. 10.1002/adhm.20220247410.1002/adhm.202202474 ↗
15. 10.1002/adma.20220783210.1002/adma.202207832 ↗
16. 10.1124/jpet.119.25870710.1124/jpet.119.258707 ↗
17. 10.1016/j.jconrel.2022.06.02710.1016/j.jconrel.2022.06.027 ↗
18. 10.1007/s00170-016-9698-610.1007/s00170-016-9698-6 ↗
19. 10.1016/j.jconrel.2022.05.04510.1016/j.jconrel.2022.05.045 ↗
20. 10.1016/j.addr.2017.08.00910.1016/j.addr.2017.08.009 ↗
21. Jennotte O Koch N Lechanteur A Evrard B. Development of amorphous solid dispersions of cannabidiol: Influence of the carrier the hot-melt extrusion parameters and the use of a crystallization inhibitor. J Drug Deliv Sci Technol. 2022;71.10.1016/j.jddst.2022.103372 ↗
22. 10.3390/molecules2718607010.3390/molecules27186070 ↗
23. 10.3390/pharmaceutics1409191510.3390/pharmaceutics14091915 ↗
24. 10.1208/s12249-020-01895-710.1208/s12249-020-01895-7 ↗
25. 10.1016/j.apsb.2021.05.01410.1016/j.apsb.2021.05.014 ↗
26. 10.1016/j.ijpharm.2022.12211510.1016/j.ijpharm.2022.122115 ↗
27. 10.1016/j.ejps.2022.10634110.1016/j.ejps.2022.106341 ↗
28. 10.1016/j.addr.2019.10.00410.1016/j.addr.2019.10.004 ↗
29. Mangang KN Thakran P Halder J Yadav KS Ghosh G Pradhan D et al. PVP-microneedle array for drug delivery: mechanical insight biodegradation and recent advances. J biomaterials Sci Polym Ed. 2022;1–32.10.1080/09205063.2022.2155778 ↗
30. 10.1002/adma.20190574010.1002/adma.201905740 ↗
31. 10.1016/j.biomaterials.2012.03.05610.1016/j.biomaterials.2012.03.056 ↗
32. 10.1039/C8RA02095G10.1039/C8RA02095G ↗
33. 10.3390/cells1012331110.3390/cells10123311 ↗
34. 10.3390/cells1004086210.3390/cells10040862 ↗
35. 10.1016/S0006-2952(03)00468-410.1016/S0006-2952(03)00468-4 ↗
36. 10.1039/C5NR06162H10.1039/C5NR06162H ↗
37. 10.1021/jacs.7b1103610.1021/jacs.7b11036 ↗
38. 10.1038/s41565-018-0319-410.1038/s41565-018-0319-4 ↗
39. 10.3390/ijms2213699510.3390/ijms22136995 ↗
40. 10.1016/j.cmet.2019.06.00110.1016/j.cmet.2019.06.001 ↗
41. 10.1007/s00580-018-2810-610.1007/s00580-018-2810-6 ↗
42. 10.1016/j.it.2019.02.00310.1016/j.it.2019.02.003 ↗
43. 10.1111/j.1600-065X.2009.00806.x10.1111/j.1600-065X.2009.00806.x ↗
44. 10.1016/j.addr.2021.02.01210.1016/j.addr.2021.02.012 ↗